Post-hoc analyses from the acoramidis initiation show rapid kidney-protective activity, including a reversible hemodynamically mediated eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P<0.05). No kidney-related adverse events were observed in these analyses, supporting a cautiously positive efficacy and safety signal.
Post-hoc analyses from the acoramidis initiation show rapid kidney-protective activity, including a reversible hemodynamically mediated eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P<0.05). No kidney-related adverse events were observed in these analyses, supporting a cautiously positive efficacy and safety signal.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
